Dicot Pharma
0.30 SEK
-21.43 %
Less than 1K followers
DICOT
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
-21.43 %
-23.75 %
+4.95 %
-3.26 %
+2.41 %
-13.66 %
+102.92 %
-54.99 %
-88.38 %
Dicot Pharma is developing the drug candidate LIB-01, which is expected to be a potency drug for the treatment of erectile dysfunction and premature ejaculation. Duration of action and fewer side effects are the main desired properties. Dicot's main strategy is to continuously evaluate industrial partnerships during the development of LIB-01 to take the drug candidate to commercialization. The company is based in Uppsala.
Read moreMarket cap
596.77M SEK
Turnover
17.57M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue K
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
30/4
2026
Interim report Q1'26
6/5
2026
General meeting '26
20/8
2026
Interim report Q2'26
All
Webcasts
Press releases
ShowingAll content types
Dicot Pharma intends to carry out an 80% already secured rights issue of SEK 210 million
Dicot Pharma publicerar årsredovisningen för 2025
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools